CLINICAL TRIALS PROFILE FOR EPOETIN ALFA

Biosimilar Clinical Trials for epoetin alfa

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01121237 ↗	MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5	Completed	Hexal AG		2010-02-01	MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring haemodialysis.
NCT01121237 ↗	MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5	Completed	Sandoz		2010-02-01	MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring haemodialysis.
NCT02140736 ↗	Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology	Completed	Hospira, Inc.		2009-09-01	The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
NCT02140736 ↗	Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology	Completed	Hospira, now a wholly owned subsidiary of Pfizer		2009-09-01	The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.

All Clinical Trials for epoetin alfa

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003681 ↗	Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome	Unknown status	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2	1998-08-01	RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. Epoetin alfa may stimulate red blood cell production and be an effective treatment for anemia in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine with or without epoetin alfa in treating patients who have myelodysplastic syndrome.
NCT00004917 ↗	Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2000-06-01	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and treat anemia in patients with head and neck cancer. It is not yet known whether receiving radiation therapy with epoetin alfa is more effective than radiation therapy alone in treating anemic patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without epoetin alfa in treating anemic patients who have head and neck cancer.
NCT00004917 ↗	Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer	Completed	Radiation Therapy Oncology Group	Phase 3	2000-06-01	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and treat anemia in patients with head and neck cancer. It is not yet known whether receiving radiation therapy with epoetin alfa is more effective than radiation therapy alone in treating anemic patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without epoetin alfa in treating anemic patients who have head and neck cancer.
NCT00006136 ↗	Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia	Completed	Boston University	Phase 2	1999-03-01	OBJECTIVES: I. Determine whether arginine butyrate with or without epoetin alfa can stimulate gamma-globin chain production to a degree that decreases anemia and results in hematologic improvement in patients with thalassemia intermedia. II. Determine whether a proportional increase in gamma-globin synthesis and mRNA and an improvement in nonalfa and alfaglobin chain imbalance by at least 10% over baseline correlate with improved hematologic response in these patients when treated with this regimen. III. Determine whether a decrease in hemolysis, as assayed by a decrease in LDH, compared to baseline levels correlates with improved hematologic response in these patients when treated with this regimen. IV. Determine whether any particular genotypes are more responsive than others to this therapy in these patients. V. Determine whether baseline epoetin alfa levels, gender, and/or baseline reticulocyte counts (or percent circulating nucleated erythroblasts) correlate with improved hematologic response in these patients when treated with this regimen.

Clinical Trial Conditions for epoetin alfa

Condition Name

Condition Name for epoetin alfa
Intervention	Trials
Anemia	185
Chronic Kidney Disease	15
Myelodysplastic Syndromes	13
Neoplasms	11

Condition MeSH

Condition MeSH for epoetin alfa
Intervention	Trials
Anemia	186
Renal Insufficiency, Chronic	66
Kidney Diseases	58
Renal Insufficiency	32

Clinical Trial Locations for epoetin alfa

Trials by Country

Trials by Country for epoetin alfa
Location	Trials
United States	888
Canada	69
Italy	55
Spain	43
France	40

Trials by US State

Trials by US State for epoetin alfa
Location	Trials
California	54
Texas	48
Florida	44
New York	39
Pennsylvania	35

Clinical Trial Progress for epoetin alfa

Clinical Trial Phase

Clinical Trial Phase for epoetin alfa
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE1	1

Clinical Trial Status

Clinical Trial Status for epoetin alfa
Clinical Trial Phase	Trials
Completed	218
Terminated	48
Unknown status	17

Clinical Trial Sponsors for epoetin alfa

Sponsor Name

Sponsor Name for epoetin alfa
Sponsor	Trials
Hoffmann-La Roche	74
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	58
Ortho Biotech Products, L.P.	30

Sponsor Type

Sponsor Type for epoetin alfa
Sponsor	Trials
Industry	312
Other	145
NIH	15

Epoetin Alfa: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 29, 2026

What is epoetin alfa’s current clinical-trials footprint?

Epoetin alfa is a long-established erythropoiesis-stimulating agent (ESA) with ongoing studies that typically focus on new patient settings, safety/tolerability, dose strategies, formulation access programs, and comparative or post-approval evidence generation. However, a complete, decision-grade “clinical trials update” requires a live trial registry pull (for example, ClinicalTrials.gov and other regional registries) with study status, start/end dates, enrollment, and endpoints. This cannot be produced to a complete and accurate standard from the information available in this chat context.

How does the epoetin alfa market break down today?

Epoetin alfa remains a foundational ESA used in anemia of chronic kidney disease (CKD), including patients on dialysis and non-dialysis populations, plus other labeled and off-label anemia contexts where erythropoiesis stimulation is clinically indicated. Market value is driven by:

• CKD prevalence and dialysis throughput
• Treatment guidelines and reimbursement rules for ESA initiation and hemoglobin targets
• Patent/biologic exclusivity history, biosimilar penetration, and tender dynamics
• Switching patterns toward biosimilar ESAs and price pressure

Market structure (pricing dynamics and competitive set)

Epoetin alfa competes in a crowded ESA market that includes originator ESAs and multiple biosimilars across regions. In most jurisdictions, biosimilar competition compresses price versus originator list pricing and shifts share toward the lowest tender-priced or formulary-preferred products.

Implication for projection: epoetin alfa’s long-term commercial outlook depends more on relative pricing and tender wins than on incremental clinical differentiation, given the class maturity.

Demand drivers by indication

Indication (high-level)	Primary demand driver	What typically constrains growth
Anemia of CKD (dialysis and non-dialysis)	CKD burden and dialysis schedules	ESA prescribing restrictions, hemoglobin target policies, and biosimilar substitution
Other ESA-labeled uses (where applicable by region)	Oncology supportive care and other anemia contexts	Safety monitoring requirements and payer limits
Off-label anemia in non-CKD contexts	Local clinical practice	Guideline variability and reimbursement gates

Note: This structure reflects typical ESA market behavior; a precise “market analysis” with country-by-country share, pricing, and forecast requires region-specific datasets that are not available in the current context.

What is the near-term and long-term market projection for epoetin alfa?

A complete projection requires at minimum:

• Baseline global and regional market size by ESA segment
• Epoetin alfa share by geography
• Expected biosimilar adoption curve and tender capture
• Indication-level volume and price forecasts

Those inputs require external market datasets and live pricing/share information that are not present here. Without those, any numeric projection would not meet a complete and accurate standard.

Where do value and risk concentrate for investors and R&D teams?

Even without a numeric forecast, epoetin alfa’s value/risk profile concentrates in a few measurable levers:

1) Biosimilar substitution and tender economics

• ESA formularies increasingly prefer biosimilar products based on contracted acquisition cost.
• Switching volumes can accelerate after payer tender cycles even if clinical practice remains stable.

Actionable lens: monitor hospital and payer formulary changes, tender award patterns, and biosimilar launch cadence.

2) Safety and label constraints

• ESAs face class-level utilization constraints tied to hemoglobin targets and thromboembolic risk mitigation.
• Clinical protocols and payer criteria influence dose intensity and discontinuation rates.

Actionable lens: treat “dose and monitoring” as commercial variables, not just clinical ones.

3) Competitive differentiation shifts from mechanism to access

Epoetin alfa’s competitive edge is usually access-based (contracting, supply reliability) rather than pharmacology, given class maturity.

Actionable lens: commercial strategy should prioritize contracting execution and supply continuity rather than claims of superiority unless supported by robust comparative outcomes.

---

Clinical and development roadmap: what tends to move the needle?

For mature ESAs like epoetin alfa, the practical development value is often in:

• Expanding evidence in specific CKD subgroups (non-dialysis, comorbid populations)
• Dose optimization in real-world settings
• Safety observation extensions and pharmacovigilance studies
• Formulation or manufacturing improvements that secure supply continuity

A “clinical trials update” with named studies, phases, endpoints, and timelines cannot be produced here to a complete and accurate standard.

---

Key Takeaways

• Epoetin alfa is a mature ESA where growth and revenue primarily track CKD anemia demand and payer/tender decisions rather than breakthrough clinical differentiation.
• A decision-grade clinical trials update requires live registry data (status, endpoints, enrollment) that cannot be generated accurately from the current context.
• A numeric market projection requires baseline market sizing, epoetin alfa share by geography, and biosimilar adoption curves, none of which are available here in a complete form.
• Commercial value and risk concentrate in biosimilar substitution dynamics, hemoglobin-target utilization constraints, and contracting execution.

FAQs

1. Is epoetin alfa still actively studied?
   Yes. ESA research continues in patient subgroups, safety monitoring, and comparative evidence generation, but a complete trials update requires registry-level data.

2. What drives epoetin alfa demand most?
   CKD prevalence and dialysis throughput, shaped by hemoglobin-target and ESA-use reimbursement criteria.

3. How does biosimilar competition affect epoetin alfa pricing?
   Biosimilar penetration typically compresses net price through tender and formulary substitution.

4. What are the main commercial risks for epoetin alfa?
   ESA utilization restrictions linked to safety policies, plus share loss from biosimilar tender wins.

5. What factors should shape market projection models?
   Regional ESA market size, epoetin alfa share, expected biosimilar adoption rate, and net pricing under tender cycles.

---

References

[1] FDA. (n.d.). Epoetin alfa product information. U.S. Food and Drug Administration.